CClinicalTrials.gg
RecruitingNCT06282562FeelFitUpdated Apr 6, 2025

FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients

An interventional study of High-Intensity Interval Training (HIIT) in Brain Tumor, Primary and Exercise, sponsored by Amsterdam UMC, location VUmc. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-06.

Sponsored by Amsterdam UMC, location VUmc · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The FeelFit study aims to assess the effectiveness of High-Intensity Interval Training (HIIT) in improving self-reported physical fitness in adult brain tumor patients during periods of stable disease, as compared to a waiting-list control group. Furthermore, several secondary and exploratory outcomes will be evaluated. The study is part of the GRIP (GuaRding quality survivorshiP) project, which aims to improve quality of life in brain tumor patients.

02

Conditions studied

  • Brain Tumor, Primary
  • Exercise

Browse trials for

03

In context

Brain Neoplasms

1,960 studies on the registry are indexed under Brain Neoplasms; 516 are open to participants now.

This study's planned enrollment of 36 is close to the median of 40 across 1,458 interventional studies indexed under Brain Neoplasms.

Browse Brain Neoplasms studies →

Lead sponsor

Amsterdam UMC, location VUmc is the lead sponsor of 302 studies on the registry; 84 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • reduced self-reported physical fitness;
  • minimum age of 18 years;
  • diagnosed with a primary brain tumor;
  • stable disease, i.e. no signs of radiological or clinical tumor progression;
  • no oncological treatment for at least two months prior to inclusion;
  • able to speak, read and write in Dutch.

Exclusion criteria

Exclusion Criteria:

  • Karnofsky Performance Score \< 70;
  • already participated in a HIIT program \< 1 month prior;
  • contraindication of exercise.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    HIIT

    The intervention group will perform High-Intensity Interval Training (HIIT), consisting of two supervised exercise sessions per week on a stationary bike, for 12 weeks. In addition, participants will receive information on general guidelines for weekly physical activity levels and will be asked to keep an exercise diary.

    Other: High-Intensity Interval Training (HIIT)

  • No intervention
    Waiting-list

    The control group on the waiting list will be given the option to perform High-Intensity Interval Training (HIIT) after their participation in the study. In addition, also participants from the waiting-list control group will receive information on general guidelines for weekly physical activity levels and will be asked to keep an exercise diary.

Interventions

  • OtherHigh-Intensity Interval Training (HIIT)

    Individualized High-Intensity Interval Training (HIIT) program with two exercise sessions per week for 12 weeks. The exercise sessions will be conducted on a stationary bike, with intensity tailored to each participant's maximum exercise capacity.

06

What researchers measure

Primary outcomes

  1. Self-reported physical fitness

    Self-reported physical fitness is measured using the first question of the International Fitness Scale (IFIS) on general physical fitness, on a 5-point scale where a higher score corresponds to better self-reported physical fitness.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

Secondary outcomes

  1. Self-reported fitness

    In addition to the first question of the International Fitness Scale (IFIS), the other questions about cardiorespiratory fitness, muscle strength, speed and flexibility will also be asked as secondary outcomes.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

  2. VO2max

    Physical fitness defined as the maximal oxygen uptake measured with a cardiopulmonary exercise test.

    Time frame: Baseline versus post-intervention (12 weeks)

Other outcomes

  1. Daily physical activity

    International Physical Activity Questionnaire (IPAQ). A higher score corresponds to a physically more intense activity.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

  2. Health-related quality of life questionnaire

    European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC-QLQ_C30) consists of 30 items and includes five functional scales, three symptom scales, a global health status/quality of life scale, and several single items assessing additional symptoms. The subscales are scored from 0-100 with higher scores representing better quality of life, better functioning, or a higher symptom burden.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

  3. Perceived functional impairments

    Work and Social Adjustment Scale (WSAS), consisting of 5 questions on a 8-point scale.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

  4. Self-efficacy

    Exercise Self-Efficacy Scale (ESES), consisting of 10 questions on a 4-point scale. A higher score indicates higher exercise self-efficacy.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

  5. Mastery

    Pearlin Mastery Scale (PMS), consisting of 7 items on a 4-point scale.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

  6. Brain tumor specific quality of life questionnaire

    European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-BN20, specific for brain tumor patients.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

  7. Subjective Happiness

    Subjective Happiness Scale (SHS), consisting of 4 questions on a 7-point scale.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

  8. Subjective cognitive functioning

    Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog), consisting of 37 items on a 5-point scale. A higher score means better cognitive functioning.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

  9. Subjective cognitive failure

    Cognitive Failure Questionnaire (CFQ), consisting of 25 items on a 5-point scale. A higher score refers to more cognitive errors.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

  10. Fatigue questionnaire

    Checklist Individual Strength (CIS20), consisting of measurements of fatigue severity, concentration problems, reduced motivation, and reduced activity.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

  11. Sleep questionnaire

    Pittsburg Sleep Quality Index (PSQI) assesses sleep dysfunction over 1-month interval.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

  12. Anxiety questionnaire

    Beck Anxiety Index (BAI), consisting of 21 questions on a 4-point scale.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

  13. Self-reported depression questionnaire

    Beck Depression Index (BDI-PC), consisting of 21 questions on a 4-point scale.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

  14. Depression questionnaire

    The Center for Epidemiologic Studies Depression questionnaire, consisting of twenty questions regarding symptoms of depression on a 4-point scale.

    Time frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)

  15. Muscle strength

    Hand-held dynamometer

    Time frame: Baseline versus post-intervention (12 weeks)

  16. Subjective physical fitness

    FitMax questionnaire, consisting of thee questions about the maximum capacity of walking, climbing, and cycling, estimating the VO2max.

    Time frame: Baseline versus post-intervention (12 weeks)

  17. Objective neurocognitive functioning

    Neuropsychological assessment (NPA), assessing different brain functions.

    Time frame: Baseline versus post-intervention (12 weeks)

  18. Objective neurological functioning

    Neurological assessment in neuro-oncology scale (NANO). A quantitative evaluation of 9 relevant neurologic domains.

    Time frame: Baseline versus post-intervention (12 weeks)

  19. Brain imaging (optional)

    MRI (magnetic resonance imaging)

    Time frame: Baseline versus post-intervention (12 weeks)

  20. Brain activity (optional)

    MEG (magnetoencephalography)

    Time frame: Baseline versus post-intervention (12 weeks)

07

Study locations

1 of 1 sites recruiting
  • VU University Medical Centers, location VUmc
    Amsterdam, 1081 HV, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06282562
Lead sponsor
Amsterdam UMC, location VUmc
Responsible party
Linda Douw (Principal Investigator, Amsterdam UMC, location VUmc) — Principal investigator
First posted
Feb 28, 2024
Start date
Jan 1, 2024
Primary completion
Aug 15, 2026 (estimated)
Completion
Aug 15, 2026 (estimated)
Last update
Apr 6, 2025

Study contacts

Marieke Blom, Msc
Contact
m.e.c.blom@amsterdamumc.nl
+31 6 21522442

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion